Drugs / B7H3 CAR-γδT cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06825455 | Mar 2025 → Dec 2027 expected | ovarian cancer, peritoneum cancer | Peking University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B7H3 CAR-γδT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06825455 ↗ |
| Action | Deplete | “the modified CAR-γδ T cells possess specific cytotoxicity against B7H3-positive tumor cells” NCT06825455 ↗ |
| Modality | Cell therapy | “γδT cells as carrier cells” NCT06825455 ↗ |
| Route | Intravenous | “intravenous infusion group” NCT06825455 ↗ |
| Target | CD276 | “B7H3 (CD276), a member of the B7 negative co-stimulatory molecule family” NCT06825455 ↗ |